Baidu
map

Nat Commun:人造血管获突破,可在受体内自行生长

2016-09-30 佚名 生物探索

导语:人工合成血管最大的挑战,莫过于设计一个能改变形状并能在受体中生长的血管,而且它还不发生免疫排斥反应。近日,明尼苏达大学的科学家突破了这个难题,他们成功开发了能随受体生长的人造血管。科学家近日表明,实验室工程改造的人工血管移植到羔羊体内能随受体生长,如果在人类身上得到证实,那么这些人工合成血管可使患者避免一些反复性的手术,相关结果发表在《Nature Communications》杂志上。人工

导语:人工合成血管最大的挑战,莫过于设计一个能改变形状并能在受体中生长的血管,而且它还不发生免疫排斥反应。近日,明尼苏达大学的科学家突破了这个难题,他们成功开发了能随受体生长的人造血管。

科学家近日表明,实验室工程改造的人工血管移植到羔羊体内能随受体生长,如果在人类身上得到证实,那么这些人工合成血管可使患者避免一些反复性的手术,相关结果发表在《Nature Communications》杂志上。

人工合成血管最大的挑战,莫过于设计一个能改变形状并能在受体中生长的血管,而且它还不发生免疫排斥反应。在该研究中,明尼苏达大学生物医学工程系Robert Tranquillo 教授及其同事在实验室中利用捐赠的皮肤细胞来制造类血管组织,并清除管内细胞使排异反应最小化,这也意味着这种血管组织可以储存,在需要时可随时进行移植。

Tranquillo 教授说,“这也是我们首次拥有现成的可移植并能在体内生长的材料,这意味着未来心脏缺陷患儿将无需进行反复性手术。”

为了开发这种材料,研究人员将绵羊皮肤细胞与纤维蛋白结合,搭建了管状组织,并利用生物反应器有节律地添加细胞生长所需的营养物质,整个培养周期为五周。生物反应器既能提供营养,又能使血管产生适当的机械性能。生物反应器由该实验室的高级研究助理Zeeshan Syedain开发,也是人工合成血管比受体动脉机械性能强的关键因素,这样一来才能保证其在受体内不被破坏。

在研究中,研究人员利用专门的洗涤剂去除管内所有的羊细胞,只留下了一个无细胞的基质,这种基质在移植时不会引起免疫反应。当将人工合成血管替代五周龄羔羊的部分肺动脉时,这些血管很快被羔羊细胞填充,且形状发生了变化并随羔羊一起成长。

Tranquillo 教授说,“更重要的是,当将其植入到羔羊体内时,羔羊细胞重新构建血管组织基质。如果没有填满细胞,血管组织将不能生长,该研究也是组织工程和再生医学的完美结合。”

在羔羊50周龄时,移植的血管直径增加了56%,血量增加了216%,胶原蛋白也增加了456%,这证明了血管不仅随时间延展,实际上还长大了。该研究未观察到凝血、血管变窄或钙化等不良反应。研究人员下一步将与医生探讨能否向FDA申请在未来几年内开展临床试验。

原始出处:

Syedain Z1, Reimer J1, Lahti M2, Berry J2, Johnson S1, Tranquillo RT1,3.Tissue engineering of acellular vascular grafts capable of somatic growth in young lambs.Nat Commun. 2016 Sep 27

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-12-23 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2017-07-14 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-11 1e1275afm36(暂无匿称)

    希望快速发展,帮助更换血管

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-06 1e0b9de5m54(暂无匿称)

    牛人发明

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-02 俅侠
  7. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-01 刘煜

    挑战,突破。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-01 刘煜

    学习了谢谢。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-01 LhtFantasy

    希望能有所突破并真正应用于临床!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2086904, encodeId=3f11208690446, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 23 20:45:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708080, encodeId=1c201e08080d8, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Thu May 18 07:45:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881347, encodeId=fa13188134e06, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 14 02:45:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144391, encodeId=5b36144391c3, content=希望快速发展,帮助更换血管, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Tue Oct 11 15:05:39 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141332, encodeId=140e1413321f, content=牛人发明, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160824/IMG57BDA6843F0F38922.jpg, createdBy=8fdd1925645, createdName=1e0b9de5m54(暂无匿称), createdTime=Thu Oct 06 21:47:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494522, encodeId=f5f81494522ba, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Oct 02 02:45:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138579, encodeId=3b841385e95d, content=挑战,突破。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:56:05 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138578, encodeId=752e1385e85d, content=学习了谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Oct 01 14:55:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138456, encodeId=8323138456ca, content=希望能有所突破并真正应用于临床!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/25/7d591af3f5a10c3198529be94f1ae8f6.jpg, createdBy=59b11629228, createdName=LhtFantasy, createdTime=Sat Oct 01 09:42:12 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138347, encodeId=33bd13834e7d, content=好样的,继续努力!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Oct 01 02:30:17 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-01 lyh994

    好样的,继续努力!

    0

相关资讯

Nat Com:实验室开发人造血管 移植后可在大型动物体内生长

最近明尼苏达大学的研究人员取得一项突破进展,他们将实验室内通过生物工程技术开发的人造血管成功地移植到小羊羔体内,并且移植血管自身还能够继续生长。如果该结果能够在人体上得到证实,这些人造血管可以使一些患有先天性心脏缺陷的儿童避免进行重复手术。这项研究发表在国际学术期刊Nature Communication上。在这项研究中,Robert Tranquillo教授及其领导的研究小组首先利用供体羊的皮肤

Baidu
map
Baidu
map
Baidu
map